US20170354666A1 - Compositions and methods for treating lysosomal disorders - Google Patents
Compositions and methods for treating lysosomal disorders Download PDFInfo
- Publication number
- US20170354666A1 US20170354666A1 US15/527,506 US201515527506A US2017354666A1 US 20170354666 A1 US20170354666 A1 US 20170354666A1 US 201515527506 A US201515527506 A US 201515527506A US 2017354666 A1 US2017354666 A1 US 2017354666A1
- Authority
- US
- United States
- Prior art keywords
- disease
- tfeb
- pparα
- agent
- fibrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 208000015439 Lysosomal storage disease Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 102100028502 Transcription factor EB Human genes 0.000 claims abstract description 169
- 101710162524 Transcription factor EB Proteins 0.000 claims abstract description 169
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 75
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 74
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229960003627 gemfibrozil Drugs 0.000 claims abstract description 59
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 46
- 230000003827 upregulation Effects 0.000 claims abstract description 37
- 229940125753 fibrate Drugs 0.000 claims abstract description 29
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 26
- 239000011719 vitamin A Substances 0.000 claims abstract description 26
- 229940045997 vitamin a Drugs 0.000 claims abstract description 26
- 229960002297 fenofibrate Drugs 0.000 claims abstract description 6
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 77
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 71
- 230000002132 lysosomal effect Effects 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 42
- 230000008436 biogenesis Effects 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 27
- 230000001965 increasing effect Effects 0.000 claims description 26
- 108020004999 messenger RNA Proteins 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 12
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 10
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 10
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 10
- 239000003524 antilipemic agent Substances 0.000 claims description 9
- 239000000833 heterodimer Substances 0.000 claims description 9
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
- 239000004299 sodium benzoate Substances 0.000 claims description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims description 8
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 7
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 7
- 208000015872 Gaucher disease Diseases 0.000 claims description 7
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 7
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 7
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 7
- 229930016911 cinnamic acid Natural products 0.000 claims description 7
- 235000013985 cinnamic acid Nutrition 0.000 claims description 7
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 7
- 229960002965 pravastatin Drugs 0.000 claims description 7
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 7
- 229960002855 simvastatin Drugs 0.000 claims description 7
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 7
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims description 7
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims description 7
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 6
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 6
- 201000002832 Lewy body dementia Diseases 0.000 claims description 6
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 230000000202 analgesic effect Effects 0.000 claims description 6
- 230000001754 anti-pyretic effect Effects 0.000 claims description 6
- 239000002221 antipyretic Substances 0.000 claims description 6
- 235000017803 cinnamon Nutrition 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
- 206010068220 Aspartylglucosaminuria Diseases 0.000 claims description 5
- 206010011777 Cystinosis Diseases 0.000 claims description 5
- 208000011518 Danon disease Diseases 0.000 claims description 5
- 208000024720 Fabry Disease Diseases 0.000 claims description 5
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 claims description 5
- 208000033149 Farber disease Diseases 0.000 claims description 5
- 208000017462 Galactosialidosis Diseases 0.000 claims description 5
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 claims description 5
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 claims description 5
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 5
- 102000016871 Hexosaminidase A Human genes 0.000 claims description 5
- 108010053317 Hexosaminidase A Proteins 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 201000008333 alpha-mannosidosis Diseases 0.000 claims description 5
- 208000024042 cholesterol ester storage disease Diseases 0.000 claims description 5
- 208000013760 cholesteryl ester storage disease Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 201000008049 fucosidosis Diseases 0.000 claims description 5
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims description 5
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims description 5
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 229960005370 atorvastatin Drugs 0.000 claims description 4
- 229960003765 fluvastatin Drugs 0.000 claims description 4
- 229960004844 lovastatin Drugs 0.000 claims description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 229960002797 pitavastatin Drugs 0.000 claims description 4
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 4
- 229960000672 rosuvastatin Drugs 0.000 claims description 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 239000011885 synergistic combination Substances 0.000 claims description 3
- 230000004642 autophagic pathway Effects 0.000 claims description 2
- 241000723347 Cinnamomum Species 0.000 claims 2
- 239000000890 drug combination Substances 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 85
- 102000023984 PPAR alpha Human genes 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 77
- 210000001130 astrocyte Anatomy 0.000 description 76
- 241000699666 Mus <mouse, genus> Species 0.000 description 65
- 230000014509 gene expression Effects 0.000 description 37
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 36
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 36
- 102000009565 Lysosomal-Associated Membrane Protein 2 Human genes 0.000 description 35
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 35
- 101100536763 Mus musculus Tfeb gene Proteins 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 32
- 108010044210 PPAR-beta Proteins 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 18
- 229960001727 tretinoin Drugs 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 210000003712 lysosome Anatomy 0.000 description 17
- 230000001868 lysosomic effect Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 239000005089 Luciferase Substances 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 11
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 11
- 238000003119 immunoblot Methods 0.000 description 11
- 108010085238 Actins Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 10
- 108010016731 PPAR gamma Proteins 0.000 description 9
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 9
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 9
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 description 9
- 210000004958 brain cell Anatomy 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 9
- 230000037356 lipid metabolism Effects 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 8
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 7
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 101150062178 Tfeb gene Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 210000002243 primary neuron Anatomy 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 101150117895 LAMP2 gene Proteins 0.000 description 5
- 108010038912 Retinoid X Receptors Proteins 0.000 description 5
- 102000034527 Retinoid X Receptors Human genes 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010217 densitometric analysis Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 102000004547 Glucosylceramidase Human genes 0.000 description 4
- 108010017544 Glucosylceramidase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 240000001987 Pyrus communis Species 0.000 description 3
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 229960001570 ademetionine Drugs 0.000 description 3
- -1 alixiers Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000003873 peroxisome proliferator activated receptor gamma antagonist Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 2
- 229940124602 FDA-approved drug Drugs 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010066463 Retinoid X Receptor alpha Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 101150092324 TPP1 gene Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 102000003802 alpha-Synuclein Human genes 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 2
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 238000011859 neuroprotective therapy Methods 0.000 description 2
- 102000027507 nuclear receptors type II Human genes 0.000 description 2
- 108091008686 nuclear receptors type II Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000858 peroxisomal effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000007111 proteostasis Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000010891 toxic waste Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 208000030954 urea cycle disease Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FVRLYIFIDKXFHU-UHFFFAOYSA-N 2-[2-(2-aminopropanoylamino)propanoylamino]-n-(4-methyl-2-oxochromen-7-yl)-3-phenylpropanamide Chemical compound C=1C=C2C(C)=CC(=O)OC2=CC=1NC(=O)C(NC(=O)C(C)NC(=O)C(N)C)CC1=CC=CC=C1 FVRLYIFIDKXFHU-UHFFFAOYSA-N 0.000 description 1
- NDFKBGWLUHKMFY-UHFFFAOYSA-N 3-[(4-anilino-2-methoxyphenyl)sulfamoyl]-2-thiophenecarboxylic acid methyl ester Chemical compound S1C=CC(S(=O)(=O)NC=2C(=CC(NC=3C=CC=CC=3)=CC=2)OC)=C1C(=O)OC NDFKBGWLUHKMFY-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 108010005254 Activating Transcription Factors Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101100000858 Caenorhabditis elegans act-3 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 102100029768 Histone-lysine N-methyltransferase SETD1A Human genes 0.000 description 1
- 101000865038 Homo sapiens Histone-lysine N-methyltransferase SETD1A Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 1
- 101000934888 Homo sapiens Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 101150009249 MAP2 gene Proteins 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 208000009795 Microphthalmos Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100013786 Mus musculus Gapdh gene Proteins 0.000 description 1
- 101100454327 Mus musculus Lamp2 gene Proteins 0.000 description 1
- 101100080282 Mus musculus Npc1 gene Proteins 0.000 description 1
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000026043 Retinoid X Receptor alpha Human genes 0.000 description 1
- 101150117538 Set2 gene Proteins 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100025393 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Human genes 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010005897 alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002621 immunoprecipitating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 229940063720 lopid Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000005060 membrane bound organelle Anatomy 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 201000010478 microphthalmia Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037352 starvation stress Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention generally relates to compositions and methods for treating lysosomal storage disorders.
- Lysosomes are membrane bound organelles containing a host of hydrolytic enzymes that are highly active in acidic milieu (1-3).
- TFEB Transcription Factor EB
- MiT/TFE microphthalmia-transcription factor E
- Tfeb The regulation of Tfeb appears to be complex and dependent on cell type and stimuli.
- a RANKL-dependent signaling pathway induces TFEB activation induced lysosomal biogenesis (13).
- Starvation or stress conditions may also activate TFEB, which otherwise is maintained in an inactivated state by mTORC1 (14, 15).
- mTORC1 14, 15
- starvation induced TFEB activity can play a vital role in lipid metabolism and that activated TFEB can also autoregulate its own gene expression (16).
- Lysosomal storage diseases are a group of approximately 50 rare inherited metabolic disorders that result from defects in lysosomal function.
- the symptoms of LSD vary, depending on the particular disorder and other variables like the age of onset, and can be mild to severe. They can include developmental delay, movement disorders, seizures, dementia, deafness and/or blindness.
- Some people with LSD have enlarged livers (hepatomegaly) and enlarged spleens (splenomegaly), pulmonary and cardiac problems, and bones that grow abnormally.
- One aspect of the present invention provides a method for treatment of a LSD.
- the method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB (TFEB).
- TFEB Transcription Factor EB
- the agent is a statin.
- the statin may be atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.
- the agent may also be, for example, a lipid-lowering drug, such as a fibrate.
- the fibrate is gemfibrozil or fenofibrate.
- the agent is an analgesic, an antipyretic, aspirin, a cinnamon metabolite, cinnamic acid, sodium phenylbutyrate or sodium benzoate.
- the composition may include a combination of at least two of the above agents.
- the composition may also include all-trans retinoic acid or vitamin A.
- the composition may include a statin or a fibrate and all-trans retinoic acid or vitamin A.
- This combination of the agent(s) with all-trans retinoic acid or vitamin A may provide a greater therapeutic effect in the subject than administration of the all-trans retinoic acid, vitamin A or the fibrate alone.
- the combination may be a synergistic combination.
- TFEB may also be upregulated by increasing Transcription Factor EB mRNA levels increasing Transcription Factor EB protein levels or activating a PPAR ⁇ -RXR ⁇ heterodimer.
- the LSD may be a neurodegenerative disorder, for example, neuronal ceroid lipofuscinosis, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS), Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or dementia with Lewy bodies (DLB).
- the LSD is a disorder of the autophagy pathway and wherein the agent increases lysosomal biogensis.
- the LSD is Tay-Sach's disease, Fabry disease, Niemann-Pick disease, Gaucher disease, Hunter Syndrome, Alpha-mannosidosis, Aspartylglucosaminuria, Cholesteryl ester storage disease, Chronic Hexosaminidase A Deficiency, Cystinosis, Danon disease, Farber disease, Fucosidosis, Galactosialidosis, or Batten disease including late infantile Batten disease and Juvenile Batten disease.
- Another aspect of the present invention provides a method for treatment of a LSD including administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of the Tfeb gene. Yet another aspect provides a method for treatment of a LSD including administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent, wherein the agent restores TFEB activity.
- FIG. 1 shows Gemfibrozil and Retinoic Acid upregulating TFEB mRNA and protein levels in brain cells.
- A, B Mouse primary astrocytes were treated with different concentrations of gemfibrozil and all-trans retinoic acid (ATRA) under serum free DMEM/F-12 medium for 12 hrs followed by monitoring mRNA levels of Tfeb by qRT-PCR (A) and TFEB protein levels by immunoblot (B).
- A gemfibrozil and all-trans retinoic acid
- G, I Mouse primary astrocytes (G) and mouse primary neurons (I) were treated with combination of gemfibrozil and retinoic acid under serum free condition for 24 hrs and were double labeled for TFEB (red)-GFAP (green) and TFEB (red)-Map2 (green), respectively.
- TFEB IR TFEB immunoreactivity
- FIG. 2 shows involvement of PPAR ⁇ and RXR ⁇ in fibrate drug-mediated upregulation of TFEB mRNA and protein:
- A, B Mouse primary astrocytes isolated from PPAR ⁇ / ⁇ and PPAR ⁇ / ⁇ and wild type mouse were treated with combination of gemfibrozil (10 ⁇ M) and retinoic acid (0.2 ⁇ M) in serum free DMEM/F12 for 24 hrs followed by monitoring the mRNA expression of Tfeb by real-time PCR (A) and protein level of TFEB by immunoblot (B).
- A real-time PCR
- B protein level of TFEB by immunoblot
- C Densitometric analysis of TFEB levels (relative to ⁇ -Actin) in PPAR ⁇ / ⁇ and PPAR ⁇ / ⁇ and wild type astrocytes.
- H, I, J Mouse primary astrocytes were untransfected, transfected with scrambled siRNA (1.0 ⁇ g) or RXR ⁇ siRNA (1.0 ⁇ g) for 36 hrs followed by treatment with RA (0.2 ⁇ M) and gemfibrozil (10 ⁇ M) in combination for 24 hrs serum free DMEM/F12 medium followed by RT-PCR for RXR ⁇ to check the level of gene silencing (H) and quantitative real time PCR for TFEB (J) and immunoblot for TFEB (J).
- FIG. 3 shows PPAR ⁇ transcriptionally regulating TFEB expression under treatment condition:
- A Map of wild-type and mutated PPRE site of TFEB-Luciferase promoter constructs.
- B BV2 cells were transfected with pTFEB(WT)-Luc for 24 hrs followed by treatment with different concentrations of gemfibrozil and retinoic acid alone and in combination and subjected to luciferase assay. p* ⁇ 0.05 vs untreated control.
- (C) BV2 cells were transfected with pTFEB(WT)-Luc for 24 hrs followed by pretreatment with PPAR ⁇ -, PPAR ⁇ -, PPAR ⁇ -antagonists followed by treatment with gemfibrozil and retinoic acid and subjected to luciferase assay. p* ⁇ 0.05 vs untreated control. p# ⁇ 0.05 vs treatment.
- FIG. 4 shows trancriptional activation of TFEB by PPAR ⁇ -RXR ⁇ -PGC1 ⁇ complex
- A Map of PPRE on TFEB promoter with core sequence and amplicon length for ChIP.
- B,C Mouse astrocytes were treated with the combination of gemfibrozil (10 ⁇ M) and RA (0.2 ⁇ M) for 30, 60, 120 and 240 mins and recruitment of PPAR ⁇ (far left), RXR ⁇ (center left), PGC1 ⁇ (center right) and RNA Polymerase (far right) on the PPRE binding site of Tfeb promoter was monitored by ChIP followed by RT-PCR (B) and qRT-PCR (C). Normal IgG was used as control. p* ⁇ 0.05 vs untreated control. All results are representative of or mean ⁇ SEM at least there independent sets of experiments.
- D Schematic representation of induction of lysosomal biogenesis by activating peroxisomal proliferators.
- FIG. 5 shows PPAR ⁇ dependant upregulation of TFEB inducing lysosomal biogenesis:
- A, B Mouse primary astrocytes isolated from PPAR ⁇ / ⁇ and PPAR ⁇ / ⁇ and wild type mouse were treated with combination of gemfibrozil (10 ⁇ M) and retinoic acid (0.2 ⁇ M) in serum free DMEM/F12 for 24 hrs followed by monitoring the mRNA expression of lysosomal genes (Lamp2 (left), Limp2 (center), Npc1(right)) by real-time PCR (A) and protein level of LAMP2 by immunoblot (B).
- gemfibrozil 10 ⁇ M
- retinoic acid 0.2 ⁇ M
- C, F, I Higher magnification images showing localization of TFEB and NeuN in the cortical neuron of mice from the treatment group (WT, PPAR ⁇ / ⁇ and PPAR ⁇ / ⁇ ).
- C, F, I Higher magnification images showing localization of LAMP2 and NeuN in the cortical neuron of mice from the treatment group (WT, PPAR ⁇ / ⁇ and PPAR ⁇ / ⁇ ).
- FIGS. 9(A)-9(D) illustrate the upregulation of TFEB mRNA expression in mouse astrocytes by cholesterol-lowering drugs (simvastatin and pravastatin), aspirin (anasgesic and anti-pyretic), cinnamic acid (metabolite of cinnamon), and drugs for urea cycle disorders (sodium phenylbutyrate and sodium benzoate).
- FIG. 10 illustrates an increase in lysosomal biogenesis by aspirin in primary mouse astrocytes.
- Cells were treated with different concentrations of aspirin for 24 h under serum-free condition followed by Lyso-tracker staining. Results represent three independent experiments.
- FIG. 11(A) -(D) shows the upregulation of LAMP2 expression by aspirin in primary mouse astrocytes.
- 11 (A) Cells were treated with 5 ⁇ M aspirin for different time periods under serum-free condition followed by monitoring the mRNA expression of LAMP2 by real-time PCR. Results are mean+SD of three different experiments. ap ⁇ 0.05 vs control; bp ⁇ 0.001 vs control.
- 11 (B) Cells were treated with different concentrations of aspirin for 24 h under serum-free condition followed by Western blot for LAMP2.
- 11 (C) Cells were treated with 5 ⁇ M aspirin for different time periods under serum-free condition followed by Western blot for LAMP2.
- 11 (D) After 24 h of aspirin treatment, cells were double-labeled for LAMP2 and GFAP. Results represent three independent experiments.
- FIG. 12(A) -(C) shows an increase in TPP1 by aspirin in primary mouse astrocytes.
- 12 (A) Cells were treated with different concentrations of aspirin for 24 h under serum-free condition followed by Western blot for TPP1.
- FIG. 13(A) -(C) illustrates the upregulation of TFEB by aspirin in primary mouse astrocytes.
- 13 (A) Cells were treated with different concentrations of aspirin for 12 h under serum-free condition followed by Western blot for TFEB. Actin was run as a house keeping molecule.
- 13 (B) Cells were treated with 5 ⁇ M aspirin for 12 h under serum-free condition followed by double-labeling with GFAP and TFEB. These results are mean of two independent experiments.
- 13 (C) Cells were transfected with p(WT)Tfeb-Luc plasmid and after 24 h of transfection, cells were stimulated with different doses of aspirin. After 4 h, firefly luciferase activity was measured in total cell extracts. Results are mean+SD of three different experiments. a p ⁇ 0.001 vs control.
- FIG. 14(A) -(B) illustrates activation of PPAR ⁇ by aspirin in primary mouse astrocytes.
- 14 (A) Cells were treated with 5 ⁇ M aspirin for different min intervals followed by isolation of nuclear extracts and electrophoretic mobility shift assay for monitoring DNA-binding activity of PPAR ⁇ using PPAR ⁇ -binding site of the Tfeb promoter as a probe.
- 14 (B) Astrocytes isolated from wild type, PPAR ⁇ ( ⁇ / ⁇ ) and PPAR ⁇ ( ⁇ / ⁇ ) mice were transfected with PPAR luciferase reporter (PPRE-x3-TK-luc) plasmid and after 24 h of transfection, cells were stimulated with different doses of aspirin. After 4 h, firefly luciferase activity was measured in total cell extracts. Results are mean+SD of three different experiments. a p ⁇ 0.001 vs control.
- FIG. 15(A) -(C) illustrates that aspirin increases the level of TFEB in astrocytes via PPAR ⁇ .
- Astrocytes isolated from WT 15 (A), PPAR ⁇ ( ⁇ / ⁇ ) 15 (B) and PPAR ⁇ ( ⁇ / ⁇ ) 15 (C) mice were treated with 5 ⁇ M aspirin for 12 h under serum-free condition followed by double-labeling for TFEB and GFAP. Results represent three independent experiments.
- FIG. 16(A) -(B) illustrates that aspirin increases the level of LAMP2 in astrocytes via PPAR ⁇ .
- Astrocytes isolated from WT, PPAR ⁇ ( ⁇ / ⁇ ) and PPAR ⁇ ( ⁇ / ⁇ ) mice were treated with different concentrations of aspirin for 24 h under serum-free condition followed by Western blot analysis for LAMP2 16 (A). Actin was run as a house keeping molecule. Bands were scanned and expressed as relative to control 16 (B). Results are mean+SD of three different experiments. a p ⁇ 0.05 vs control; b p ⁇ 0.001 vs control. ns, not significant.
- FIGS. 17(A) -(C) illustrate that aspirin increases lysosomal biogenesis in astrocytes via PPAR ⁇ .
- Astrocytes isolated from WT 17 (A), PPAR ⁇ ( ⁇ / ⁇ ) 17 (B) and PPAR ⁇ ( ⁇ / ⁇ ) 17 (C) mice were treated with 5 ⁇ M aspirin for 24 h under serum-free condition followed by Lyso-tracker staining. Results represent three independent experiments.
- the term subject refers to a human or veterinary subject.
- therapeutic effect means an effect which induces, ameliorates or otherwise causes an improvement in the pathological symptoms, disease progression or physiological conditions associated with or resistance to succumbing to a disorder, for example a LSD, of a subject.
- therapeutically effective amount as used with respect to a drug means an amount of the drug which imparts a therapeutic effect to the subject.
- synergy mean more than the expected additive effect of a combination.
- a synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined, unit dosage formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen.
- LSD lysosomal storage disorder
- the LSD may be, for example, Tay-Sach's disease, Fabry disease, Niemann-Pick disease, Gaucher disease, Hunter Syndrome, Alpha-mannosidosis, Aspartylglucosaminuria, Cholesteryl ester storage disease, Chronic Hexosaminidase A Deficiency, Cystinosis, Danon disease, Farber disease, Fucosidosis, Galactosialidosis or Batten disease including late infantile Batten disease and Juvenile Batten disease.
- the LSD may also be a neurodegenerative disease involving the autophagy-lysosome pathway, for example, neuronal ceroid lipofuscinosis, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS), Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or dementia with Lewy bodies (DLB).
- the neurodegenerative disorder may be characterized by defective autophage. Such disorders include Alzheimer's, Parkinson's disease, and Huntington's disease.
- One embodiment includes administering to a subject suffering from a LSD an agent that upregulates or enhances expression from the Tfeb gene.
- Upregulation may include increasing mRNA levels for Tfeb.
- the methods of the present invention also include administering to a subject suffering from a LSD an agent that upregulates TFEB or restores TFEB activity.
- Upregulation may include increasing TFEB mRNA levels, increasing TFEB protein levels, or increasing TFEB activity.
- Activating a PPAR ⁇ /RXR ⁇ heterodimer results in upregulation of TFEB.
- the inventor has also surprisingly shown that TFEB is upregulated through the activity or involvement of PPAR ⁇ , but not PPAR ⁇ or PPAR ⁇ .
- the agent may be a lipid-lowering drug such as a fibrate.
- the fibrate may be gemfibrozil, fenofibrate, or clofibrate.
- the agent may be all-trans retinoic acid or vitamin A.
- administration of the fibrate in combination with all-trans retinoic acid or vitamin A to the subject may upregulate TFEB more than administration of the fibrate or all-trans retinoic acid or vitamin A alone.
- the fibrate and all-trans retinoic acid or vitamin A when administered together to the subject, may cooperatively enhance upregulation of TFEB to synergistically upregulate TFEB.
- a lower dose of the fibrate may be needed in the presence of all-trans retinoic acid or vitamin A to achieve the same degree of TFEB upregulation as occurs when only a higher dose of the fibrate is administered to the subject.
- the combination of the fibrate and all-trans retinoic acid or vitamin A may be a synergistic combination.
- the lipid lowering drug is a statin.
- the statin may be atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination of at least two of these drugs.
- the statin or statins may be used alone or in combination with a fibrate and or all-trans retinoic acid or vitamin A.
- the agent may be an analgesic or antipyretic, for example aspirin; phenylbutyrate; sodium benzoate; or a cinnamon metabolite, for example cinnamic acid.
- such agents may be used in combination with all-trans retinoic acid or vitamin A and may be administered together to the subject to cooperatively enhance upregulation of TFEB to synergistically upregulate TFEB.
- the lipid lowering drugs may be drugs that reduce the level of triglycerides circulating in the blood of the subject. Additionally, lipid-lowering drugs may be drugs that decrease the risk of hyperlipidemia.
- the fibrate may mediate upregulation of TFEB via PPAR ⁇ , but not PPAR ⁇ and PPAR ⁇ . During upregulation of TFEB, PPAR ⁇ forms a heterodimer with RXR- ⁇ and the RXR ⁇ /PPAR-a heterodimer is recruited to the promoter of the Tfeb gene via a RXR binding site.
- the upregulation of TFEB may also be mediated by all-trans retinoic acid. All-trans retinoic acid may also be known as ATRA, retinoic acid, tretinoin, and vitamin A acid. All-trans retinoic acid may mediate upregulation of TFEB via the retinoid X receptor- ⁇ (RXR- ⁇ ). During upregulation of TFEB, RXR- ⁇ forms a heterodimer with peroxisome proliferator-activated receptor-a (PPAR- ⁇ ) and the RXR- ⁇ /PPAR- ⁇ heterodimer is recruited to the promoter of the Tfeb gene via a RXR binding site.
- All-trans retinoic acid may also be known as ATRA, retinoic acid, tretinoin, and vitamin A acid. All-trans retinoic acid may mediate upregulation of TFEB via the retinoid X receptor- ⁇ (RXR- ⁇ ).
- RXR- ⁇ forms a heterodi
- the composition mediating upregulation of TFEB may include a combination of the agent, for example, a lipid lowering drug, and all-trans retinoic acid or vitamin A.
- a combination may cooperatively mediate or enhance upregulation of TFEB as compared to administration of the agent or all-trans retinoic acid or vitamin A alone.
- the combination may cooperatively enhance upregulation of TFEB about 2-fold, about 3-fold, about 4-fold, about 5-fold, or about 10-fold as compared to administration of the lipid-lowering drug or all-trans retinoic acid or vitamin A alone.
- the combination may cooperatively enhance upregulation of TFEB about 3-fold as compared to administration of the lipid-lowering drug or all-trans retinoic acid or vitamin A alone.
- compositions including at least one of the agents disclosed above.
- the pharmaceutical composition may also include all-trans retinoic acid or vitamin A.
- the pharmaceutical composition may include gemfibrozil or a combination of gemfibrozil and all-trans retinoic acid or vitamin A or a combination of aspirin and all-trans retinoic acid or vitamin A.
- compositions can be in the form of, for example, tablets, pills, dragees, hard and soft gel capsules, granules, pellets, aqueous, lipid, oily or other solutions, emulsions such as oil-in-water emulsions, liposomes, aqueous or oily suspensions, syrups, alixiers, solid emulsions, solid dispersions or dispersible powders.
- the agent may be admixed with commonly known and used adjuvants and excipients, for example, gum arabic, talcum, starch, sugars (such as, e.g., mannitose, methyl cellulose, lactose), gelatin, surface-active agents, magnesium stearate, aqueous or non-aqueous solvents, paraffin derivatives, cross-linking agents, dispersants, emulsifiers, lubricants, conserving agents, flavoring agents (e.g., ethereal oils), solubility enhancers (e.g., benzyl benzoate or benzyl alcohol) or bioavailability enhancers (e.g. GELUCIRE).
- the agent may also be dispersed in a microparticle, e.g. a nanoparticulate, composition.
- the agent or pharmaceutical compositions of the agent can be dissolved or suspended in a physiologically acceptable diluent, such as, e.g., water, buffer, oils with or without solubilizers, surface-active agents, dispersants or emulsifiers.
- a physiologically acceptable diluent such as, e.g., water, buffer, oils with or without solubilizers, surface-active agents, dispersants or emulsifiers.
- oils for example and without limitation, olive oil, peanut oil, cottonseed oil, soybean oil, castor oil and sesame oil may be used.
- the agent or pharmaceutical compositions of the agent can be in the form of an aqueous, lipid, oily or other kind of solution or suspension or even administered in the form of liposomes or nano-suspensions.
- the agents disclosed above or pharmaceutical compositions including these agents can be administered by any method that allows for the delivery of a therapeutic effective amount of the agent to the subject.
- Modes of administration can include, but are not limited to, oral, topical, transdermal and parenteral routes, as well as direct injection into a tissue, and delivery by a catheter.
- Parenteral routes can include, but are not limited to subcutaneous, intradermal, intra-articular, intravenous, intraperitoneal and intramuscular routes.
- the route of administration is by topical or transdermal administration, such as by a lotion, cream, a patch, an injection, an implanted device, a graft or other controlled release carrier.
- Routes of administration include any route which directly delivers the composition to the systemic circulation (e.g., by injection), including any parenteral route.
- One embodiment of the method of the present invention comprises administering at least one agent, for example gemfibrozil or a combination of gemfibrozil and ATRA, in a dose, concentration and for a time sufficient to prevent the development of, or to lessen the extent of, a LSD.
- Certain embodiments include administering systemically at least one agent in a dose between about 0.1 micrograms and about 100 milligrams per kilogram body weight of the subject, between about 0.1 micrograms and about 10 milligrams per kilogram body weight of the subject, between about 0.1 micrograms and about 1 milligram per kilogram body weight of the subject.
- the agent or therapeutic composition containing the agent can be administered in a single daily dose or in multiple doses per day. This treatment method may require administration over extended periods of time.
- the amount per administered dose or the total amount administered will be determined by the physician and will depend on such factors as the mass of the patient, the age and general health of the patient and the tolerance of the patient to the compound.
- DMEM/F-12 50/50 1 ⁇ , Hank's balanced salt solution (HBSS) and 0.05% trypsin were purchased from Mediatech (Washington, D.C.).
- Fetal bovine serum (FBS) was obtained from Atlas Biologicals (Fort Collins, Colo.).
- Antibioticantimycotic, gemfibrozil and all trans retinoic acid (ATRA) were obtained from Sigma-Aldrich (St. Louis, Mo.).
- Astroglia were isolated from mixed glial cultures as described (24, 25) according to the procedure of Giulian and Baker (26). Briefly, on day 9, the mixed glial cultures were washed three times with Dulbecco's modified Eagle's medium/F-12 and subjected to shaking at 240 rpm for 2 h at 37° C. on a rotary shaker to remove microglia. After 2 days, the shaking was repeated for 24 h for the removal of oligodendroglia and to ensure the complete removal of all nonastroglial cells. The attached cells were seeded onto new plates for further studies.
- Fetal (E18-E16) mouse neurons were prepared as previously described (27) with modifications. Whole brains were removed and the cells were washed by centrifugation three times at 1200 rpm for 10 min, the pellet dissociated and the cells plated at 10% confluence in 8-well chamber slides pre-treated for >2 hr with Poly-D-Lysine (Sigma, St. Louis, Mo.). After 4 min, the non-adherent cell suspension was aspirated and 500 ml complete Neurobasal media (Invitrogen) supplemented with 2% B27 was added to each well. The cells were incubated for 4 days prior to experimentation.
- Neurobasal media Invitrogen
- Double-label immunofluorescence with ⁇ -tubulin and either GFAP or CD11b revealed that neurons were more than 98% pure (data not shown).
- the cells were stimulated with gemfibrozil in Neurobasal media supplemented with 2% B27 minus antioxidants (Invitrogen) for 24 hr prior to methanol fixation and immunostaining.
- RT-PCR Semi-Quantitative Reverse Transcriptase-Coupled Polymerase Chain Reaction
- Mouse Tfeb Sense, (SEQ ID NO.: 1) 5′-AAC AAA GGC ACC ATC CTC AA-3′; Antisense, (SEQ ID NO.: 2) 5′-CAG CTC GGC CAT ATT CAC AC-3′; Mouse Lamp2: Sense, (SEQ ID NO.: 3) 5′-GGT GCT GGT CTT TCA GGC TTG ATT-3′; Antisense, (SEQ ID NO.: 4) 5′-ACC ACC CAA TCT AAG AGC AGG ACT-3′; Mouse Limp2: Sense, (SEQ ID NO.: 5) 5′-TGT TGA AAC GGG AGA CAT CA-3′; Antisense, (SEQ ID NO.: 6) 5′-TGG TGA CAA CCA AAG TCG TG-3′; Mouse Npc1: Sense, (SEQ ID NO.: 7) 5′-GGG ATG CCC GTG CCT GCA AT-3′; Antisense, (SEQ ID NO.
- Amplified products were electrophoresed on 2% agarose (Invitrogen) gels and visualized by ethidium bromide (Invitrogen) staining.
- Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA was used as a loading control to ascertain that an equivalent amount of cDNA was synthesized from each sample.
- the mRNA quantification was performed using the ABIPrism7700 sequence detection system (Applied Biosystems, Foster City, Calif.) using SYBR Select master mix (Applied Biosystems).
- the mRNA expression of the targeted genes was normalized to the level of Gapdh mRNA and data was processed by the ABI Sequence Detection System 1.6 software.
- Immunocytochemistry was performed as described earlier (29). Briefly, 8 well chamber slides containing mouse primary astrocytes, mouse neurons were cultured to 70-80% confluence were fixed with chilled Methanol (Fisher Scientific, Waltham, Mass.) overnight, followed by two brief rinses with filtered PBS.
- DAPI 4′,6-diamidino-2-phenylindole
- mice After 60 days of treatment, mice were sacrificed and their brains fixed, embedded, and processed. Sections were made from different brain regions and for immunofluorescence staining on fresh frozen sections, anti-mouse TFEB (1:500), anti-mouse LAMP2 (1:200) and anti-mouse NeuN (1:500) were used. The samples were mounted and observed under Olympus BX41 fluorescence microscope (30).
- Fibroblasts cultured to 70-80% confluence were subjected to different stimuli under reduced serum (2%) DMEM medium followed by incubation with 75 nM LysoTracker Red DND99 (Invitrogen) for 45 mins. Cells were then washed thoroughly with filtered PBS and mounted on glass slides and viewed under BX41 fluorescence microscope
- membranes were then washed for 15 min in TBS plus Tween 20 (TBST) and blocked for 1 hr in TBST containing BSA. Next, membranes were incubated overnight at 4° C. under shaking conditions with the following 1° antibodies; TFEB (1:1000, Abcam), LAMP2 (1:500, Abcam) and ⁇ -actin (1:800; Abcam, Cambridge, Mass.). The next day, membranes were washed in TBST for 1 hr, incubated in 2° antibodies against 1° antibody hosts (all 1:10,000; Jackson ImmunoResearch) for 1 hr at room temperature, washed for one more hour and visualized under the Odyssey® Infrared Imaging System (Li-COR, Lincoln, Nebr.).
- Mouse genomic DNA isolated from primary mouse astrocytes was used as the template during PCR.
- the 5′ flanking sequence of the mouse TFEB ( ⁇ 916/+61) gene was isolated by PCR.
- Primers were designed from gene bank sequences.
- Tfeb sense: 5′-acgcgt CCA GGA GCC AGG GAC GGG GTA CAT CTC-3′ (SEQ ID NO.: 11); antisense: 5′-agatct AAG GAG AAA CTG AGT CCG GGC AGA AGG-3′ (SEQ ID NO.: 12).
- the sense primer was tagged with an Mlu1 restriction enzyme site while the antisense primer was tagged with Bgl II.
- the PCR was performed using an Advantage-2 PCR kit (Clontech) according to the manufacturer's instruction.
- the resulting fragments were gel purified and ligated into the PGEM-TEasy vector (Promega). These fragments were further subcloned into the PGL-3 Enhancer vector after digestion with corresponding restriction enzymes and verification by sequencing ACGT Inc. DNA Sequencing Services.
- Site-directed mutagenesis was done by using the site directed mutagenesis kit (Stratagene, USA). Two primers in opposite orientation were used to amplify the mutated plasmid in a single PCR reaction.
- the primer sequence for mutated promoter site were: Mutated: Sense: 5′-GCA ACA GCA AGT GCG GAT TTG AGG GGG GGG GAC GGT GGG-3′ (SEQ ID NO.: 13); Antisense: 5′-CCC ACC GTC CCC CCC CCT CAA ATC CGC ACT TGC TGT TGC-3′ (SEQ ID NO.: 14).
- the PCR product was precipitated with ethanol and then phosphorylated by T4 kinase.
- the phosphorylated fragment was self-ligated by T4 DNA ligase and digested with restriction enzyme DpnI to eliminate the non-mutated template.
- the mutated plasmid was cloned and amplified in Escherichia coli (DH5- ⁇ strain) competent cells.
- ChIP assays were performed using method described by Nelson et al (35), with certain modifications. Briefly, mouse primary astrocytes were stimulated by 10 ⁇ M gemfibrozil and 0.5 ⁇ M RA together for 6 hrs followed by fixing with formaldehyde (1.42% final volume) and quenching with 125 mM Glycine. The cells were pelleted and lysed in IP buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, NP-40 (0.5% vol/vol), Triton X-100 (1.0% vol/vol).
- Chelex/protein G bead suspension was allowed to cool to room temperature. Proteinase K (100 ⁇ g/ml) was then added and beads were incubated for 30 min at 55° C. while shaking, followed by another round of boiling for 10 min. The suspension was centrifuged and supernatant collected. The Chelex/protein G beads fraction was vortexed with another 100 ⁇ l water, centrifuged again, and the first and the second supernatants were combined. Eluate was used directly as a template in PCR.
- the following primers were used to amplify fragments flanking RXR binding element in the mouse Tfeb promoter: Set1: sense: 5′-GAA CAT TCC AGG TGG AGG CA-3′ (SEQ ID NO.: 15), antisense: 5′-CCC CCA ACA CAT GCT TCT CT-3′ (SEQ ID NO.: 16); Set2: sense: 5′-GAG TCT CTC GGA GGA GGT GA-3′ (SEQ ID NO.: 17), antisense: 5′-ACT CCA GGC ATG CTT TCT CC-3′(SEQ ID NO.: 18).
- the PCRs were repeated by using varying cycle numbers and different amounts of templates to ensure that results were in the linear range of PCR.
- the qRT-PCR was performed using the same primers and SYBR select mastermix. Data were normalized to input and non-specific IgG and fold increase vs control was calculated.
- Protein blots were analyzed using ImageJ (NIH, Bethesda, Md.) and bands were normalized to their respective ⁇ -actin loading controls. Data are representative of the average fold change with respect to control for at least 25 different images per condition from three independent set of experiments.
- PPAR activators like the FDA-approved drug gemfibrozil, where examined to determine if they could upregulate the expression of TFEB in mouse brain cells. Since it has been known that PPAR ⁇ and RXR ⁇ forms a transcriptionally active complex (21, 36, 37), we used both gemfibrozil and ATRA, which activates RXR ⁇ , to check if there is any additive effect due to dual treatment.
- Mouse primary astrocytes (MPA) were treated in serum free media with single doses of gemfibrozil and ATRA and also in combination. Quantitative realtime PCR data showed increased expression of Tfeb in all three groups with the increase being marginally higher in combinatorial treatment (but not statistically significant w.r.t individual treatments) ( FIG. 1A ).
- FIGS. 1G & 1I The TFEB immunoreactivity was quantified using ImageJ and we observed ⁇ 4-fold increase in the overall levels of TFEB and ⁇ 5-6-fold increase of TFEB localization of TFEB in the nucleus upon treatment ( FIGS.
- Example 3 PPAR ⁇ and RXR ⁇ are Involved in the Drug Mediated Upregulation of TFEB
- PPAR ⁇ coactivator-1a (PGC1A) could be involved in transcriptionally activating Tfeb, so we tested whether PPAR ⁇ is involved in this particular drug mediated expression of TFEB by using PPAR ⁇ inhibitors.
- Western blot for TFEB using pretreatment with PPAR ⁇ specific inhibitors prior to treatment with the drugs indicate that gemfibrozil and ATRA may not be using the PPAR ⁇ mediated pathway for the upregulation of TFEB ( FIGS. 2D & 2E ).
- PPAR ⁇ and RXR ⁇ have been known to form a transcriptional complex and our data showed marginal increase of TFEB in presence of ATRA. We wanted to see whether ATRA exerts its effects via RXR ⁇ .
- WT MPAs were treated with RXR ⁇ specific siRNA followed by treatment with the combination of gemfibrozil and ATRA and both mRNA and protein analyses were performed.
- the data showed a successful knockdown of RXR ⁇ gene and consequently the effect of drugs were partially abrogated in absence of RXR ⁇ , which was evident from the levels of Tfeb mRNA after RXR ⁇ silencing ( FIGS. 2H & 2I ).
- the western blot also showed similar results with the TEFB levels being significantly less in RXR ⁇ silenced cells compared to scrambled siRNA after treatment ( FIGS. 2J & 2K ). Taken together these data indicate that PPAR ⁇ and RXR ⁇ could be involved in the upregulation of TFEB by gemfibrozil and ATRA.
- PPAR ⁇ and RXR ⁇ together form a transcriptional complex, so having determined that those receptors appear to upregulate Tfeb, we tested whether the receptors transcriptionally regulate Tfeb expression.
- Tfeb Peroxisomal Proliferator Response Element
- pTFEB(WT) The Tfeb promoter containing the PERO was cloned into the pGL3 Enhancer vector.
- pTFEB(Mu) was also cloned into PGL3 vector.
- the Wild type luciferase construct when transfected into BV2 cells showed marked increase in the luciferase activity ( FIG. 3B ).
- the cells containing the pTFEB(WT) luciferase construct were treated with PPAR ⁇ -antagonist (GW6471; 250 nM), PPAR ⁇ -antagonist (GSK0660; 250 nM), PPAR ⁇ -antagonist (GW9662; 5 nM) we observed the luciferase activity was similar to the untreated cells in PPAR ⁇ antagonist treated cells, but not in the PPAR ⁇ - or PPAR ⁇ -antagonist treated cells ( FIG. 3C ).
- TFEB is the master regulator of lysosomal gene expression and biogenesis (9,12,16) so we expected an increase in the biogenesis and lysosomal markers with the upregulation of TFEB.
- the MPAs treated under the same condition were subjected to mRNA analysis for some lysosomal markers like Lamp2, Limp2 and Npc1. As expected the data showed elevated levels of those genes under treatment conditions in WT and PPAR ⁇ ( ⁇ / ⁇ ) cells, but not in PPAR ⁇ ( ⁇ / ⁇ ) cells.
- FIG. 5A Western blot analysis and immunocytochemistry for LAMP2 in WT and K.O. cells showed a similar protein expression pattern as well ( FIGS. 5B, 5C & 5D ).
- Example 6 Agonists of PPAR ⁇ and RXR ⁇ Induce Lysosomal Biogenesis In Vivo in the CNS of WT and PPAR ⁇ / ⁇ , but not in PPAR ⁇ / ⁇ , Mice
- Example 8 Discussion of Examples 2 to 7
- Lysosomes are one of the major organelles in cells that not only act as the waste management machinery of the cell but also play significant roles in other biological processes like antigen presentation, regulation of certain hormones, bone remodeling, necrotic cell death, cell surface repair, and developmental and other signaling pathways (2, 43-47). In order to carry out these varied functions the biogenesis and activity of lysosomes needs to be tightly regulated. According to recent findings, TFEB is a master regulator of lysosomal biogenesis (9, 12, 15). Over the years different groups have underscored the role of lysosome in different disease scenarios (48-53).
- Lysosome-related genes are reported to be closely regulated in the orbital fat of patients suffering from Graves' ophthalmopathy whereas down-regulation of lysosomal processing improved pegylated lipopolyplex-mediated gene transfection (53, 54).
- the increase in lysosomal biogenesis may not necessarily prove to be beneficial in all disease and cell types, but in some cases induction of the autophagy-lysosomal pathway could be helpful for cellular clearance of toxic wastes (55, 56).
- TFEB transcription factor EB
- TFEB was shown to rescue the activity of a ⁇ -hexosaminidase mutant.
- the findings describe TFEB as specific regulator of lysosomal proteostasis and a therapeutic target to rescue enzyme homeostasis in LSDs (60,61).
- TFEB has become a potentially important transcription factor for its role in not only lysosomal biogenesis but also due to its implications as a therapeutic target in disease conditions.
- PPAR ⁇ has been shown to play significant role in different regulatory and modulatory pathways (67-71).
- Certain polyunsaturated fatty acids and oxidized derivatives and by lipid-modifying drugs of the fibrate family, including fenofibrate and gemfibrozil has been known to activate PPAR ⁇ .
- Fibrate drugs replace the HSP90 repressor complex which sequesters PPAR ⁇ in the cytosol and help to rescue the transcriptional activity of PPAR ⁇ (21). Therefore, we assessed the role of the PPAR group of receptors for this phenomenon.
- Our data clearly indicate the involvement of PPAR ⁇ , but not PPAR ⁇ and PPAR ⁇ , in the process of upregulation of TFEB by gemfibrozil.
- the in vitro studies were further validated by in vivo studies, in which we used the knockout mice for PPAR ⁇ and PPAR ⁇ . Our in vivo results also supported the cell culture data.
- the luciferase assay results using both WT and mutant luciferase construct of the PERO on the Tfeb promoter showed increased Tfeb promoter dependant activity in the WT construct upon stimulation.
- PPAR ⁇ ( ⁇ / ⁇ ) cells when transfected with pTFEB(WT)-Luc construct and also WT cells when transfected with pTFEB(Mu)-Luc construct did not show any significant increase in the luciferase activity.
- the ChIP data indicated the recruitment of the PPAR ⁇ and RXR ⁇ along with PGC1 ⁇ and RNA Pol on the PERO site of the TFEB promoter. The experimental data was critically analyzed along with incorporation of proper controls to ensure the specificity of the findings.
- FIG. 9 illustrates the upregulation of TFEB mRNA expression in mouse astrocytes by cholesterol-lowering drugs (simvastatin and pravastatin), aspirin (anasgesic and anti-pyretic), cinnamic acid (metabolite of cinnamon), and drugs for urea cycle disorders (sodium phenylbutyrate and sodium benzoate).
- Mouse primary astrocytes were incubated with different concentrations (see FIG. 9 ) of simvastatin and pravastatin (A), (B), cinnamic acid (C), and sodium phenylbutyrate and sodium benzoate (D) for 5 hr. under serum-free condition followed by monitoring the mRNA expression of TFEB by semi-quantitative RT-PCR.
- Sodium formate (D) was used as a negative control for sodium phenylbutyrate and sodium benzoate.
- LAMP2 is an important lysosomal membrane protein, which plays a key role in the formation of new lysosomes.
- FIG. 11A time-dependent increase in LAMP2 mRNA
- FIG. 11C protein expression by aspirin in astrocytes.
- FIG. 11B LAMP2 increase by aspirin was further confirmed by immunostaining.
- TPP1 Tripeptidylpeptidase 1
- astrocytes Tripeptidylpeptidase 1
- FIG. 12A Increase in TPP1 protein in response to 5 ⁇ M aspirin was evident as early as 2 h, which was maximum at 12 h of incubation ( FIG. 12B ).
- FIG. 12C we observed increase in TPP1 activity at 2 and 5 ⁇ M, but not 10 ⁇ M, aspirin ( FIG. 12C ).
- TFEB is a master regulator of lysosomal biogenesis (9, 12, 25).
- Lysosome-related genes are reported to be closely regulated in the orbital fat of patients suffering from Graves' ophthalmopathy whereas down-regulation of lysosomal processing improved pegylated lipopolyplex-mediated gene transfection (53, 54).
- the increase in lysosomal biogenesis may not necessarily prove to be beneficial in all disease and cell types, but in some cases induction of the autophagy-lysosomal pathway could be helpful for cellular clearance of toxic wastes (55, 56).
- TFEB transcription factor EB
- PGC1 ⁇ transcription factor EB
- TFEB has been shown to rescue the activity of a ⁇ -hexosaminidase mutant.
- PPAR ⁇ plays a key role in the transcription of Tfeb. Therefore, here, we examined if aspirin could induce the activation of PPAR ⁇ in astrocytes.
- ESA electrophoretic mobility shift assay
- Example 15 Aspirin Upregulates TFEB in Primary Mouse Astrocytes Via PPAR ⁇
- FIG. 15 shows that aspirin induced the expression of TFEB in astrocytes isolated from WT and PPAR ⁇ ( ⁇ / ⁇ ), but not PPAR ⁇ ( ⁇ / ⁇ ), mice.
- Example 17 Discussion of Examples 10 to 16
- aspirin has been widely used as an analgesic throughout the world for decades. On the other, it can be taken orally, the least painful route. Although aspirin has been reported to exhibit some toxic effects (gastric ulcers, stomach bleeding, and tinnitus etc.) at high doses (74), in our study, aspirin is boosting lysosomal biogenesis at low doses (2 and 5 ⁇ M) and at low doses, aspirin may not be toxic. However, if aspirin exhibits any toxic effects even at lower doses (e.g. gastric ulcer), there are ways to reduce its side effects.
- enteric-coated aspirin is available for oral use and to avoid the degradation in the stomach.
- low dose of aspirin in slow-releasing formulation showed efficacy as an anti-platelet agent (75) without much noticeable side effect.
- SAM S-adenosyl-methionine
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/527,506 US20170354666A1 (en) | 2014-11-19 | 2015-11-16 | Compositions and methods for treating lysosomal disorders |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462081696P | 2014-11-19 | 2014-11-19 | |
US15/527,506 US20170354666A1 (en) | 2014-11-19 | 2015-11-16 | Compositions and methods for treating lysosomal disorders |
PCT/US2015/060878 WO2016081365A1 (en) | 2014-11-19 | 2015-11-16 | Compositions and methods for treating lysosomal disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/060878 A-371-Of-International WO2016081365A1 (en) | 2014-11-19 | 2015-11-16 | Compositions and methods for treating lysosomal disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/036,138 Division US12023345B2 (en) | 2014-11-19 | 2020-09-29 | Compositions and methods for treating lysosomal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170354666A1 true US20170354666A1 (en) | 2017-12-14 |
Family
ID=56014423
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/527,506 Abandoned US20170354666A1 (en) | 2014-11-19 | 2015-11-16 | Compositions and methods for treating lysosomal disorders |
US17/036,138 Active 2036-02-15 US12023345B2 (en) | 2014-11-19 | 2020-09-29 | Compositions and methods for treating lysosomal disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/036,138 Active 2036-02-15 US12023345B2 (en) | 2014-11-19 | 2020-09-29 | Compositions and methods for treating lysosomal disorders |
Country Status (9)
Country | Link |
---|---|
US (2) | US20170354666A1 (ja) |
EP (2) | EP3220906B1 (ja) |
JP (4) | JP2017536363A (ja) |
KR (1) | KR20170083146A (ja) |
CN (1) | CN107205976A (ja) |
AU (1) | AU2015350223B2 (ja) |
CA (2) | CA3176253A1 (ja) |
ES (1) | ES2914085T3 (ja) |
WO (1) | WO2016081365A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020176432A1 (en) * | 2019-02-25 | 2020-09-03 | Rush University Medical Center | Compositions including cinnamic acid and methods of use thereof |
EP3796939A4 (en) * | 2018-05-22 | 2022-03-23 | Duke University | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES WITH RIFAXIMIN |
EP3876932A4 (en) * | 2018-11-05 | 2022-07-20 | Rush University Medical Center | NASAL DELIVERY OF LOW-DOSE ASPIRIN FOR THE TREATMENT OF NEURODEGENERATIVE AND LYSOSOMAL STORAGE DISEASES |
CN114929237A (zh) * | 2019-10-01 | 2022-08-19 | 西洛斯治疗有限公司 | 海藻糖制剂及其用途 |
WO2023114414A1 (en) * | 2021-12-16 | 2023-06-22 | The United States Government As Represented By The Department Of Veterans Affairs | Benzoic acid salts for treatment of nervous system injuries and disorders |
EP4028025A4 (en) * | 2019-09-09 | 2023-07-19 | University of Pittsburgh - of the Commonwealth System of Higher Education | METHODS OF RESTORING LYSOSOMAL FUNCTION OF RETINAL PIGMENT EPITHELIAL CELLS BY TFEB ACTIVATION |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3220906B1 (en) * | 2014-11-19 | 2022-03-02 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
JP6958922B2 (ja) * | 2016-06-13 | 2021-11-02 | シニュークス インターナショナル(タイワン)コーポレイション | 安息香酸ナトリウムの共結晶及びその使用 |
TWI736635B (zh) | 2016-06-13 | 2021-08-21 | 心悅生醫股份有限公司 | 苯甲酸鋰之共晶及其用途 |
CN110167545A (zh) * | 2016-12-29 | 2019-08-23 | 拉什大学医学中心 | 吉非罗齐对晚期婴儿型神经元蜡样质脂褐质沉积症患者寿命的增加和自发活动的改善 |
EP3580237A1 (en) * | 2017-02-08 | 2019-12-18 | Novartis AG | Fgf21 mimetic antibodies and uses thereof |
JP2021511799A (ja) * | 2018-01-30 | 2021-05-13 | ラッシュ ユニヴァーシティ メディカル センター | 組織および細胞の多重分析のための連続染色 |
WO2019156252A1 (ja) * | 2018-02-06 | 2019-08-15 | 国立大学法人京都大学 | ライソゾーム病の予防及び治療剤 |
WO2020142748A1 (en) | 2019-01-03 | 2020-07-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for increasing transcription factor eb polypeptide levels |
US12042476B2 (en) * | 2022-02-04 | 2024-07-23 | Mcmaster University | Methods for the treatment of lysosomal storage diseases |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002501887A (ja) | 1998-01-28 | 2002-01-22 | ワーナー−ランバート・カンパニー | アルツハイマー病の治療方法 |
US20010028895A1 (en) | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
BRPI0509374A (pt) * | 2004-03-29 | 2007-09-11 | Wyeth Corp | suplementos nutricionais multivitamìnicos e minerais |
US20060135612A1 (en) * | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
ES2246737B1 (es) * | 2005-06-09 | 2006-12-01 | Jose Juan Rodriguez Jerez | "composicion farmaceutica que comprende lisina y usos correspondientes". |
JP2009084155A (ja) * | 2006-01-16 | 2009-04-23 | Kanazawa Univ | レビー小体病治療薬及びレビー小体病予防薬 |
US20070225360A1 (en) | 2006-03-22 | 2007-09-27 | L'oreal | Anti-aging composition containing phloretin |
GB0718824D0 (en) * | 2007-09-26 | 2007-11-07 | Univ Ramot | Methods of treating lysosomal storage disorders |
US20120114670A1 (en) * | 2007-10-02 | 2012-05-10 | University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
US9388413B2 (en) * | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
US9388414B2 (en) * | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
JP2010106001A (ja) * | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ppar活性化剤 |
EP2218458A1 (en) * | 2009-02-13 | 2010-08-18 | Fondazione Telethon | Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof |
PT2995306T (pt) * | 2009-10-19 | 2019-03-29 | Amicus Therapeutics Inc | Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal |
WO2012120048A1 (en) * | 2011-03-07 | 2012-09-13 | Fondazione Telethon | Tfeb phosphorylation inhibitors and uses thereof |
AU2012272815B2 (en) * | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
PL399467A1 (pl) * | 2012-06-08 | 2013-12-09 | 3G Therapeutics Inc. | Zastosowanie genisteiny do obnizania poziomu zwiazków organicznych spichrzanych w komórkach w leczeniu i/lub zapobieganiu lizosomalnych chorób spichrzeniowych (LChS) |
US9750712B2 (en) * | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
EP3220906B1 (en) * | 2014-11-19 | 2022-03-02 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
-
2015
- 2015-11-16 EP EP15861122.8A patent/EP3220906B1/en active Active
- 2015-11-16 AU AU2015350223A patent/AU2015350223B2/en active Active
- 2015-11-16 CN CN201580073947.8A patent/CN107205976A/zh active Pending
- 2015-11-16 US US15/527,506 patent/US20170354666A1/en not_active Abandoned
- 2015-11-16 CA CA3176253A patent/CA3176253A1/en active Pending
- 2015-11-16 WO PCT/US2015/060878 patent/WO2016081365A1/en active Application Filing
- 2015-11-16 KR KR1020177016827A patent/KR20170083146A/ko not_active Application Discontinuation
- 2015-11-16 ES ES15861122T patent/ES2914085T3/es active Active
- 2015-11-16 EP EP22151969.7A patent/EP4026545A1/en active Pending
- 2015-11-16 CA CA2967066A patent/CA2967066A1/en active Pending
- 2015-11-16 JP JP2017526853A patent/JP2017536363A/ja active Pending
-
2019
- 2019-12-24 JP JP2019232644A patent/JP2020100621A/ja active Pending
-
2020
- 2020-09-29 US US17/036,138 patent/US12023345B2/en active Active
-
2021
- 2021-04-05 JP JP2021063971A patent/JP2021107404A/ja active Pending
- 2021-09-21 JP JP2021153206A patent/JP2022003060A/ja not_active Withdrawn
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3796939A4 (en) * | 2018-05-22 | 2022-03-23 | Duke University | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES WITH RIFAXIMIN |
EP3876932A4 (en) * | 2018-11-05 | 2022-07-20 | Rush University Medical Center | NASAL DELIVERY OF LOW-DOSE ASPIRIN FOR THE TREATMENT OF NEURODEGENERATIVE AND LYSOSOMAL STORAGE DISEASES |
WO2020176432A1 (en) * | 2019-02-25 | 2020-09-03 | Rush University Medical Center | Compositions including cinnamic acid and methods of use thereof |
EP4028025A4 (en) * | 2019-09-09 | 2023-07-19 | University of Pittsburgh - of the Commonwealth System of Higher Education | METHODS OF RESTORING LYSOSOMAL FUNCTION OF RETINAL PIGMENT EPITHELIAL CELLS BY TFEB ACTIVATION |
CN114929237A (zh) * | 2019-10-01 | 2022-08-19 | 西洛斯治疗有限公司 | 海藻糖制剂及其用途 |
WO2023114414A1 (en) * | 2021-12-16 | 2023-06-22 | The United States Government As Represented By The Department Of Veterans Affairs | Benzoic acid salts for treatment of nervous system injuries and disorders |
Also Published As
Publication number | Publication date |
---|---|
ES2914085T3 (es) | 2022-06-07 |
JP2020100621A (ja) | 2020-07-02 |
WO2016081365A1 (en) | 2016-05-26 |
US20230037062A1 (en) | 2023-02-02 |
JP2022003060A (ja) | 2022-01-11 |
US12023345B2 (en) | 2024-07-02 |
CN107205976A (zh) | 2017-09-26 |
KR20170083146A (ko) | 2017-07-17 |
JP2017536363A (ja) | 2017-12-07 |
JP2021107404A (ja) | 2021-07-29 |
AU2015350223A1 (en) | 2017-05-11 |
AU2015350223B2 (en) | 2021-04-01 |
CA2967066A1 (en) | 2016-05-26 |
CA3176253A1 (en) | 2016-05-26 |
EP3220906B1 (en) | 2022-03-02 |
EP4026545A1 (en) | 2022-07-13 |
EP3220906A4 (en) | 2018-04-25 |
EP3220906A1 (en) | 2017-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12023345B2 (en) | Compositions and methods for treating lysosomal disorders | |
Ghosh et al. | Activation of peroxisome proliferator-activated receptor α induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders | |
US11351142B2 (en) | Composition and method for treating neuronal ceroid lipofuscinosis | |
Park et al. | Anti-inflammatory effects of aromatic-turmerone through blocking of NF-κB, JNK, and p38 MAPK signaling pathways in amyloid β-stimulated microglia | |
Chinnici et al. | The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old | |
Zhong et al. | Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress | |
Marwarha et al. | Palmitate-induced endoplasmic reticulum stress and subsequent C/EBPα homologous protein activation attenuates leptin and Insulin-like growth factor 1 expression in the brain | |
Launay et al. | Autophagy induction halts axonal degeneration in a mouse model of X-adrenoleukodystrophy | |
Feng et al. | Oxidative stress in the neurodegenerative brain following lifetime exposure to lead in rats: Changes in lifespan profiles | |
Gentile et al. | Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake | |
Yao et al. | Free radicals and lipid peroxidation do not mediate β-amyloid-induced neuronal cell death | |
Bai et al. | Attenuation of Pb-induced Aβ generation and autophagic dysfunction via activation of SIRT1: Neuroprotective properties of resveratrol | |
Jiang et al. | Icariin Ameliorates Amyloid Pathologies by Maintaining Homeostasis of Autophagic Systems in Aβ 1–42-Injected Rats | |
Cerquone Perpetuini et al. | Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors | |
Abd El Aziz et al. | Neuroprotective effects of telmisartan and nifedipine against cuprizone-induced demyelination and behavioral dysfunction in mice: roles of NF-κB and Nrf2 | |
US11844767B2 (en) | Composition and methods for stimulating clearance of amyloid-beta protein | |
US20210015807A1 (en) | Alk5 inhibitors as skeletal muscle hypertrophy inducers | |
Xu et al. | Activation of neuregulin 1/ErbB signaling is involved in the development of TOCP-induced delayed neuropathy | |
Han et al. | Novel organoselenides (NSAIDs-Se derivatives) protect against LPS-induced inflammation in microglia by targeting the NOX2/NLRP3 signaling pathway | |
Yang et al. | Smilagenin induces expression and epigenetic remodeling of BDNF in alzheimer's disease | |
Wei et al. | The antioxidant ESeroS-GS inhibits NO production and prevents oxidative stress in astrocytes | |
Yang et al. | Neuroprotective effects of Hu-Yi-Neng, a diet supplement, on SH-SY5Y human neuroblastoma cells | |
Hu et al. | MS275 reduces seizure-induced brain damage in developing rats by regulating p38 MAPK signaling pathways and epigenetic modification | |
WO2022217035A1 (en) | Activators of integrated stress response pathway for protection against ferroptosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RUSH UNIVERSITY MEDICAL CENTER, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PAHAN, KALIPADA;REEL/FRAME:042413/0668 Effective date: 20141124 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |